Tests artery-delivered neuroprotective drugs after stroke clot removal
Tests drugs given through an artery in adults with ischemic stroke after clot removal.
Plain-language title generated from the registry record
Registry title: Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute ischemic stroke who can have endovascular treatment, to test the safety of giving a protective drug through an artery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute ischemic stroke, with endovascular treatment possible
Main reasons for not taking part
- Modified Rankin Score above 2 because of an earlier stroke
- Blood clotting problems, bleeding tendency or low platelets (<80000/mm3)
- Severe liver or kidney problems, or needing dialysis
- Severe high blood pressure (systolic over 200mmHg or diastolic over 110 mmHg)
- Judged unsuitable for the study by the researcher
Read by machine on 9 November 2026.
Where in China
- Department of Neurology, General Hospital of Northern Theater CommandShenyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hui-Sheng Chen
- Trial code
- NCT04664933
- Record updated
- 11 September 2026
- Original description
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.Read full original descriptionShow less
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.
Inclusion: Age ≥18 years; Acute ischemic stroke patients who is eligible for endovascular treatment; Signed informed consent.
Exclusion: Modified Rankin Score >2 caused by a history of prior stroke; Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (<80000/mm3); Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg); Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; Unsuitable for this clinical studies assessed by researcher.